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OBJECTIVE: To set up regional assistant systems, inte-
grate health resources and advocate high-quality health
service, Department of Health in Taiwan promotes the
4th Health Network-New Era Health Care Program in
central of Taiwan. One of the major issues is to promote
public health education. We set up an educational
program to promote appropriate medication concept 
to the public and students in communities in central 
of Taiwan. METHODS: Supported by Department of
Health and conducted for one year, this was a prospec-
tive program consisting of training workshops for 
community pharmacists, developing and implementing
surveys, and public educational promotion. The major
issues of public educational promotions include appro-
priate use of medication, especially those about general
medication use, antimicrobial agents and being alert
against drug abuse. Even though 34 community pharma-
cists were recommended from four pharmacy associations
in central Taiwan and participated in the training work-
shops, only 8 pharmacists were qualiﬁed as instructor
pharmacists according to the results of questionnaire and
realistic demonstration after training and evaluating.
During 3 months, we held 13 promotions; 6 of them were
held in communities and 7 in schools. To evaluate the out-
comes of promotions, we conducted a pre- and post-
promotion survey via questionnaires. Questionnaires
included general information, medication information
resources and medication knowledge. RESULTS: A total
of 226 participates in communities were distributed with
115 post-promotion survey (51%) and of 475 partici-
pates in schools were distributed with 410 (86%) post-
promotion survey. The pre-promotion results showed
that 57.07% community participators and 77.48% 
students got medication information from more than 2
sources. After promotions, the results showed that med-
ication knowledge improved signiﬁcantly in schools and
community participators (p < 0.05). CONCLUSIONS:
We can ﬁnd out that it sure is a good opportunity for
pharmacists to contact the public through well-designed
promotion activities and beneﬁt the healthcare systems.
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OBJECTIVES: Anxiety disorders are among the most
common mental health conditions in the United States but
study of their impact on labor productivity has been
limited. The objective of this study was to estimate the
annual indirect costs due to anxiety disorders in the U.S.
population. METHODS: Retrospective analysis was con-
ducted of the 1999 Medical Expenditure Panel Survey
(MEPS). The MEPS provided data from a nationally 
representative sample of 24,618 respondents and their
medical care and health insurance providers and employ-
ers. Data extracted for this study included medical con-
ditions and employment information comprised of hourly
earnings, hours worked per week, and disability days.
Anxiety disorders were deﬁned using the current Diag-
nostic and Statistical Manual of Mental Disorders (DSM-
IV-TR) and were mapped to corresponding ICD-9-CM
codes and included anxiety and panic disorders, stress
disorders, obsessive compulsive disorder, and phobias.
Patients with an anxiety disorder who incurred absence
from work were identiﬁed using ICD-9-CM codes and
variables denoting disability days. Indirect costs were 
calculated for patients who missed workdays using the
human capital approach. Sample estimates were weighted
and projected to the population and 95% conﬁdence
limits were calculated using the Taylor expansion
method. RESULTS: As a percentage of the population,
the number of patients with an anxiety disorder who
missed workdays was low, at 0.20 percent (95% CL =
0.13 to 0.27). However, the associated indirect costs were
substantial, estimated at $2,981,633,568. Mean indirect
costs were $5347 per patient who missed workdays. Rel-
ative to the entire population, mean indirect costs per
person were $10.79. CONCLUSIONS: Although the
prevalence of anxiety disorders resulting in absenteeism
was found to be relatively low, the corresponding losses
in productivity were almost $3 billion. This suggests long-
term disability associated with these conditions and high-
lights the importance of early diagnosis and treatment to
minimize work loss.
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OBJECTIVES: To compare “homeopathic drugs” 
strategy (strategy H) with “psychotropic drugs” strategy
(strategy P) for treating anxiety disorders in France, 
in terms of effectiveness, satisfaction, and costs.
METHODS: Effectiveness, satisfaction, and economic
data were derived from a 3-month pragmatic prospective
study including 394 patients which were “male or 
female over 18, who consulted a homeopathic or non-
homeopathic GP for the ﬁrst time for symptoms of
anxiety disorders such as deﬁned by the DSM IV”. Strat-
egy H included 135 patients that received at least one
homeopathic drug and no psychotropic drugs, and strat-
egy P 185 patients that received at least one psychotropic
drug and no homeopathic drugs. In both strategies, other
drugs could have been prescribed (trace elements, etc).
Effectiveness was assessed by GPs using the “Hamilton
Anxiety Scale”, and by patients using the “Spielberger
State Trait Anxiety Inventory.” Satisfaction of GPs and
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patients was evaluated using the “Likert Scale.” Direct
medical costs (medical visits, medication, additional tests)
were assessed from the national health insurance system
viewpoint, using public prices and French Social Se-
curity tariffs. We checked the comparability of patient 
population and performed appropriate statistical tests:
Chi-Square test for qualitative variables, and Student,
Mann-Whitney, Kolmogorov-Smirnov tests for quantita-
tive variables. RESULTS: The “homeopathic drugs”
strategy was statistically equivalent to the “psychotropic
drugs” strategy in terms of effectiveness (absolute varia-
tion of Hamilton score: 13.11 vs 13.02, absolute varia-
tion of Spielberger Ya and Yb scores: 14.85 vs 18.65 and
10.41 vs 13.28 respectively) and satisfaction (no statisti-
cal differences), for signiﬁcantly lower direct medical
costs reimbursed by the national health insurance system
(€53.46 vs €65.75). CONCLUSION: Homeopathic 
drugs could constitute a cost-effective alternative to psy-
chotropic drugs for treating anxiety disorders, and so
could provide an answer to public health and economic
problems posed by these drugs in France.
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OBJECTIVES: Anxiety disorders have been estimated to
cost $46.6 billion annually in the United States. Social
Anxiety Disorder (SAD) is among the most prevalent and
most chronic of the anxiety disorders, but there is a lack
of information on its economic impact. SSRIs have been
proven to be effective in the prevention of relapse but
further cost-effectiveness studies are required. This study
evaluated the cost-effectiveness of escitalopram in 
comparison with placebo in relapse prevention of SAD.
METHODS: The clinical study was conducted in outpa-
tients (18–80 years) with a primary diagnosis of gener-
alised SAD (DSM-IV) and an LSAS score 370. After 12
weeks of open-label treatment (10–20mg/day escitalo-
pram), responders were randomised to 24 weeks of 
escitalopram (n = 190) or placebo (n = 181) treatment,
to assess the relapse rate. In addition to clinical evalua-
tions, quality of life (SF-36) was assessed at baseline, and
at Weeks 12 and 24 of treatment. The use of medical ser-
vices and absence from work were recorded for the cal-
culation of direct and indirect costs from the perspective
of society. RESULTS: Patients treated with escitalopram
experienced a better quality of life compared to placebo-
treated patients (better scores for all the mental health-
related dimensions: social functioning, role emotional,
mental health; p < 0.05, and vitality, p < 0.10) and expe-
rienced fewer relapses. (The cumulative relapse rate at
Week 24 was 23% for the escitalopram group versus
56% for the placebo group.) Total costs were 22.5%
lower for patients treated with escitalopram compared to
placebo (€255 versus €329; difference not statistically sig-
niﬁcant at the 5% conﬁdence level). Relapse appears to
be an important cost driver. CONCLUSIONS: Thus, con-
tinuation of escitalopram treatment is effective in the pre-
vention of relapse in SAD patients. Escitalopram is more
cost-effective than placebo and the drug purchase costs
are more than offset by a decrease in total costs.
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OBJECTIVES: Social Anxiety Disorder (SAD) is a
chronic disabling psychiatric disorder. SSRIs are recog-
nized as effective ﬁrst-line treatment, but relapse rates as
high as 60% have been reported when treatment is 
discontinued. Inappropriate treatment of this condition
places signiﬁcant economic burdens upon society. The
aim of this study was to compare costs and the impact
on quality of life of relapsed SAD patients with a control
group of non-relapsed patients. METHODS: An eco-
nomic evaluation conducted alongside a double-blind,
placebo-controlled, 9-month relapse prevention clinical
study was used to compare the quality of life and costs
for relapsed and non-relapsed patients. Relapse was either
an increase of the Liebowitz Social Anxiety Scale (LSAS)
total score of at least 10 points or as judged by the clin-
ician. Quality of life assessments (SF-36) were made at
baseline, and at weeks 12 and 24 of treatment. Medical
services usage and sick leave days were calculated from
the societal perspective. RESULTS: At the end of the 
6-months, 133 patients had relapsed and 238 were still
in remission. Total costs at endpoint were higher for
relapsed patients compared to non-relapsed patients
(€337 versus €265). Sick leave was the main cost driver.
The likelihood of needing sick leave was 14% and 7%
for relapsed and non-relapsed patients, respectively (p =
0.047) with fewer days of sick leave for non-relapsed
patients. Relapsed patients had a poorer quality of life
compared to non-relapsed patients (lower scores for all
the mental health related dimensions: social functioning,
role emotional, mental health and vitality; p < 0.001).
CONCLUSIONS: Relapsed patients have a poorer
quality of life and incur higher costs. This highlights the
need for drugs that are effective in preventing relapse in
SAD patients.
